A systematic review and meta-analysis found significantly higher circulating lipocalin-2 levels in patients with metabolic dysfunction-associated steatotic liver disease compared ...
A newly published review presents a clinical stratification framework that connects MASLD subtypes, risk profiling, and diagnostic tools to personalized ...
A two-cohort human transcriptomic study demonstrates that elevated MDK expression and suppressed fatty-acid beta-oxidation form a reciprocal transcriptional signature in ...
An 11-protein signature from circulating extracellular vesicles, validated in an independent cohort, was associated with advanced fibrosis in MASH and ...
An integrative RNA sequencing and machine learning study identified a seven-gene signature and key liver cell subpopulations associated with advanced ...
Researchers have developed a k-mer-based estimator that accurately measures substitution rates in highly repetitive genomic sequences where existing tools like ...
A new review builds an evidence-tiered framework for predicting GLP-1 therapy response in fatty liver disease using host genotype and ...
A spatial transcriptomics study of 16 MASH patients and eight controls maps compartment-specific CYP450 suppression, immune activation, and disrupted cell-cell ...
A preclinical mouse study found that Gudan Wan reduced liver injury, inflammation and fibrosis while altering autophagy- and apoptosis-related proteins, ...
A review finds that microbial metabolites may influence variable responses to MASH therapies, but direct clinical evidence linking gut microbial ...
A new review proposes that lipid metabolism plays fundamentally different roles at each stage of fatty liver disease progression to ...
A Duke-NUS pre-clinical study has created the first diet-induced mouse model of lean MASH, showing that excess dietary salt can ...
A phase-2 randomized trial shows intermittent dasatinib plus quercetin significantly improved liver fibrosis and resolved MASH in nearly half of ...
Tirzepatide, a novel therapeutic agent, has emerged as a beacon of hope for individuals grappling with metabolic dysfunction-associated steatohepatitis (MASH). ...
